Jan 18 (Reuters) - Mesoblast Ltd MSB.AX:
FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY
MESOBLAST LTD - SECOND PHASE 3 TRIAL MSB-DR004 OVER 50% ENROLLED
MESOBLAST LTD - SIGNIFICANT PAIN REDUCTION AND OPIOID CESSATION IN PHASE 3 TRIAL
MESOBLAST LTD - REXLEMESTROCEL-L RECEIVES RMAT DESIGNATION FROM FDA
Source text: ID:nGNX1Qh23k
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.